Why Viking Therapeutics Stock Popped Today

Core Viewpoint - Viking Therapeutics is positioned for potential growth in the obesity treatment market, with a significant focus on its upcoming phase 3 clinical trials for the GLP-1 drug VK2735, despite facing competition from established players like Novo Nordisk and Eli Lilly [1][2]. Company Summary - Truist Securities analyst Joon Lee has lowered the price target for Viking Therapeutics from $95 to$75, citing increasing competition in the obesity space, yet still views 2025 as a critical year for the company [1]. - Viking Therapeutics aims to become a major player in the weight loss market, potentially joining Novo Nordisk and Eli Lilly, with even a small market share in the multibillion-dollar GLP-1 drug market being significant for the company's financials [2]. - The company currently has no revenues and is considered speculative, but achieving any drug market entry would be a notable success [3]. Financial Projections - Analysts predict Viking Therapeutics will generate less than $2 million in revenue for the current year, with expectations of rapid growth to$38 million by 2027 and reaching $729 million by 2029, the year analysts anticipate the company will turn a profit [4].